SLS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SLS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. SELLAS Life Sciences Group's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-3.83 Mil. SELLAS Life Sciences Group's Total Assets for the quarter that ended in Sep. 2023 was $8.09 Mil.
The historical rank and industry rank for SELLAS Life Sciences Group's Equity-to-Asset or its related term are showing as below:
During the past 13 years, the highest Equity to Asset Ratio of SELLAS Life Sciences Group was 0.77. The lowest was -0.78. And the median was 0.38.
The historical data trend for SELLAS Life Sciences Group's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SELLAS Life Sciences Group's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where SELLAS Life Sciences Group's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
SELLAS Life Sciences Group's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as
Equity to Asset (A: Dec. 2022 ) | = | Total Stockholders Equity | / | Total Assets |
= | 4.851 | / | 20.943 | |
= | 0.23 |
SELLAS Life Sciences Group's Equity to Asset Ratio for the quarter that ended in Sep. 2023 is calculated as
Equity to Asset (Q: Sep. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | -3.827 | / | 8.086 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SELLAS Life Sciences Group (NAS:SLS) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of SELLAS Life Sciences Group's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Angelos M. Stergiou | director, officer: President and CEO | C/O SELLAS LIFE SCIENCES GROUP, INC., 2000 CROW CANYON PLACE, SUITE 380, SAN RAMON CA 94583 |
Barbara A Wood | officer: EVP, Gen. Counsel, Corp. Sec. | 58 S SERVICE RD, MELVILLE NY 11747 |
John Thomas Burns | officer: VP, Finance & Corp Controller | 16760 SW UPPER BOONES FERRY RD, SUITE 101, PORTLAND X1 97224 |
Katherine Bach Kalin | director | 3201 CARNEGIE AVENUE, CLEVELAND OH 44115 |
Robert Francomano | officer: Chief Commercial Officer | C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, 11TH FLOOR, NEW YORK NY 10022 |
Nicholas J. Sarlis | officer: Chief Medical Officer and SVP | C/O SELLAS LIFE SCIENCES GROUP, INC., 2000 CROW CANYON PLACE, STE. 380, SAN RAMON CA 94583 |
Stephen F Ghiglieri | director | C/O NEUROGESX INC., 981 INDUSTRIAL ROAD SUITE F, SAN CARLOS CA 94070 |
Jane Wasman | director | C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
David A Scheinberg | director | 325 CENTRAL PARK W, APT 38, NEW YORK NY 10025 |
Van Nostrand Robert L | director | C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511 |
John Varian | director | ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
Eqc Private Markets Sac Fund Ltd-eqc Biotech Sely Ii Fund` | 10 percent owner | C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08 |
Eqc Private Markets Sac Fund Ltd-eqc Biotech Sely I Fund | 10 percent owner | C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08 |
Equilibria Capital Management Ltd | 10 percent owner | O'HARA HOUSE, ONE BERMUDIANA ROAD, HAMILTON D0 HM08 |
Eqc Private Markets Ii Sac Fund Ltd-eqc Biotech Sely Iii Fund | 10 percent owner | C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08 |
From GuruFocus
By sperokesalga 04-18-2023
By Value_Insider 12-06-2022
By Stock market mentor 01-19-2023
By Value_Insider 12-08-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.